Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: BECKER
Liczba odnalezionych rekordów: 3



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/3

Tytuł oryginału: Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly.
Autorzy: Caron Ph., Beckers A., Cullen D. R., Goth M. I., Gutt B., Laurberg P., Pico A. M., Valimaki M., Zgliczyński W.
Źródło: J. Clin. Endocrinol. Metab. 2002: 87 (1) s.99-104, il., tab., bibliogr. 22 poz.
Sygnatura GBL: 310,620

Hasła klasyfikacyjne GBL:
  • endokrynologia
  • farmacja

    Typ dokumentu:
  • praca kliniczna
  • praca opublikowana za granicą
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new ong-acting formulation in a large population of acromegalic patients previously responsive to lanreotide 30 mg, im (substained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 ń 1.2 yr). All patients had been treated with lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48 p.c.), 10 d (32 p.c.), or 7 d (20 p.c.). Treatment was switched from lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of lanreotide Autogel, mean lanreotide levels were similar to those obtained at steady state with lanreotide 30 mg. During lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previoulsy achived during lanreotide 30 mg treatment. After 3 injections of lanreotide Autogel, mean GH (2.87 ń 0.22 ng/ml) and IGF-I (317 ń 15 ng/ml) values were comparable with those recorded at the end of lanreotide 30 mg treatment (GH, 2.82 ń 0.19 ng/ml; IGF-I, 323 ń 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achived in 33 p.c. and 39 p.c. of patients during lanreotide 30 mg and lanreotide Autogel treatment, respectively...

    2/3

    Tytuł oryginału: Stan uzębienia dzieci 8-letnich w Bielsku-Białej.
    Tytuł angielski: State of the dentition in 8 year olds from Bielsko-Biała.
    Autorzy: Truszel Marek, Roztoczyńska Agata, Becker Katarzyna
    Źródło: Mag. Stomatol. 2002: 12 (7/8) s.12-15, il., tab., bibliogr. 17 poz., sum.
    Sygnatura GBL: 312,932

    Hasła klasyfikacyjne GBL:
  • stomatologia
  • pediatria

    Typ dokumentu:
  • praca epidemiologiczna

    Wskaźnik treści:
  • ludzie
  • dzieci 6-12 r.ż.
  • płeć męska
  • płeć żeńska

    Streszczenie polskie: W pracy oceniono stan uzębienia populacji 8-latków zamieszkałych w Bielsku-Białej, określając frekwencję i intensywność próchnicy (osobno dla zębów mlecznych i stałych), higienę jamy ustnej oraz częstość występowania i rodzaje wad zgryzu. Zebrane dane poddano analizie statystycznej.

    3/3

    Tytuł oryginału: Radioiodine-treatment (RIT) of functional thyroidal autonomy.
    Autorzy: Meller Johannes, Sahlmann C. O., Becker Wolfgang
    Źródło: Nucl. Med. Rev. 2002: 5 (1) s.1-10, il., tab., bibliogr. 72 poz.
    Sygnatura GBL: 313,603

    Hasła klasyfikacyjne GBL:
  • endokrynologia
  • radiologia

    Typ dokumentu:
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: Since 1942, therapy with radioiodine (RIT) has gained a major role in the treatment of benign thyroid disorders, notably hyperthyroidism caused by Graves' disease or toxic multinodular goitre (thyroid autonomy). In iodine deficient areas thyroid autonomy accounts for 40-50 p.c. of all cases with hyperthyroidism. RIT has become a cost-effective first-line procedure in autonomy-patients with latent or overt hyperthyroidims, especially in the absence of a large goitre, after thyroid surgery and in elderly patients with latent or overt hyperthyroidims, especially in the absence of a large goitre, after thyroid surgery and in elderly patients with associated conditions who carry a high intra- or perioperative risk. Decisions concerning the definitive treatment of thyroid autonomy should take into account previous episodes of hyperthyroidism, objective parameters of risk stratification in euthyroid patients as well as concomitant diseases and the probability of iodine exposure in the future. In Central Europe the majority of investigators prefer to estimate the therapeutic activity individually by a radioiodine test. TCTUs (global 99m-Tc-pertechnetate thyroid uptake under suppression) - based dose concepts have been proven to be highly effective in the elimination of autonomy and carry a low ( 10 p.c.) risk of postradioiodtherapeutic hypothyriodism. Radioiodine therapy for autonomy has been found to be both effective and safe and without major early or late side effects. The most frequent complication is hypothyroidism requiring lifelong follow-up.

    stosując format: